Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: A double-blind, parallel controlled trial during an influenza pandemic year

Influenza and other Respiratory Viruses

Volumn 7, Issue 5, 2013, Pages 854-862

  Bennett, Alayne L ^a   Smith, David W ^a,b   Cummins, Martin J ^c   Jacoby, Peter A ^d   Cummins, Joseph M ^c   Beilharz, Manfred W ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c Amarillo Biosciences Inc   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Influenza; Interferon; Low dose; Oromucosal

Indexed keywords

ALPHA INTERFERON; INFLUENZA VACCINE; PLACEBO;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMMON COLD; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAY FEVER; HEADACHE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TREATMENT OUTCOME; VIRAL RESPIRATORY TRACT INFECTION;

INFLUENZA; INTERFERON; LOW DOSE; OROMUCOSAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-ALPHA; MALE; MIDDLE AGED; RESPIRATORY TRACT DISEASES; YOUNG ADULT;

EID: 84882713817     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12094     Document Type: Article

References (39)

1. World Health Organization. Fact Sheet No 211:Seasonal Influenza. 2009. Available at http://www.who.int/mediacentre/factsheets/fs211/en/index.html (Accessed 2 November 2010).
2. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086-5096.
3. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edn. Canberra: National Health and Medical Research Council, 2003.
4. Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009; 15:365-371.
5. Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1-60.
6. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009; 69:2523-2531.
7. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999; 19:817-828.
8. Hall CB, Douglas RG Jr, Simons RL. Interferon production in adults with respiratory syncytial viral infection. Ann Intern Med 1981; 94:53-55.
9. McIntosh K. Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr 1978; 93:33-36.
10. Soloviev V. The results of controlled observations on the prophylaxis of influenza with interferon. Bull World Health Organ 1969; 41:683-688.
11. Jordan W, Hopps H, Merigan T. Influenza and interferon research in the Soviet Union. J Infect Dis 1973; 128:261-264.
12. Merigan TC, Reed SE, Hall TS, Tyrrell DA. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973; 1:563-567.
13. Phillpots RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS, Sheperd WM. Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984; 4:535-541.
14. Treanor JJ, Betts RF, Erb SM, Roth FK, Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J Infect Dis 1987; 156:379-383.
15. Hayden F, Mills S, Johns M. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis 1983; 148:914-921.
16. Farr BM, Gwaltney JM Jr, Adams KF, Hayden FG. Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother 1984; 26:31-34.
17. Monto AS, Albrecht JK, Schwartz SA. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. Antimicrob Agents Chemother 1988; 32:47-50.
18. Sperber SJ, Hayden FG. Antiviral chemotherapy and prophylaxis of viral respiratory disease. Clin Lab Med 1987; 7:869-896.
19. Bosio E, Beilharz MW, Watson MW, Lawson CM. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J Interferon Cytokine Res 1999; 19:869-876.
20. Bosio E, Cluning CL, Beilharz MW. Low-dose orally administered type I interferon reduces splenic B cell numbers in mice. J Interferon Cytokine Res 2001; 21:721-728.
21. Beilharz MW, Cummins JM, Bennett AL. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 2007; 355:740-744.
22. Beilharz MW, McDonald W, Watson MW, Heng J, McGeachie J, Lawson CM. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res 1997; 17:625-630.
23. Satoh Y, Kasama K, Kuwabara M et al. Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma. J Interferon Cytokine Res 1999; 19:887-894.
24. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49:585-593.
25. Brod SA, Nguyen M, Hood Z, Shipley GL. Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 2006; 26:150-155.
26. Beilharz MW, Cummins M, Bennett A, Cummins J. Oromucosal administration of interferon to humans. Pharmaceuticals 2010; 3:323-344.
27. Fukuda S, Ando S, Sanou O et al. Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ. Lymphokine Res 1988; 7:175-185.
28. Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine 2008; 26:2135-2141.
29. Sezaki H, Suzuki F, Kawamura Y et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54:1317-1324.
30. Hayashi J, Kishihara Y, Ueno K et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998; 158:177-181.
31. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000; 100:384-390.
32. Pelfrey CM, Cotleur AC, Lee JC, Rudick RA. Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J Neuroimmunol 2002; 130:211-223.
33. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009; 10:509-516.
34. Vuorinen T, Meurman O. Enzyme immunoassays for detection of IgG and IgM antibodies to parainfluenza types 1, 2 and 3. J Virol Methods 1989; 23:63-70.
35. Gao L, Yu S, Chen Q et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine 2010; 28:4445-4451.
36. United States Centers for Disease Control and Prevention. Influenza symptoms and the role of laboratory diagnostics. 2011. Available at http://www.cdc.gov/flu/professionals/diagnosis/labrolesprocedures.htm (Accessed 18 January 2012).
37. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-384.
38. Isomura S, Ichikawa T, Miyazu M et al. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J 1982; 25:131-137.
39. Haasbach E, Droebner K, Vogel AB, Planz O. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. J Interferon Cytokine Res 2011; 31:515-525.